Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Allergic Asthma Favors Brucella Growth in the Lungs of Infected Mice.

Machelart A, Potemberg G, Van Maele L, Demars A, Lagneaux M, De Trez C, Sabatel C, Bureau F, De Prins S, Percier P, Denis O, Jurion F, Romano M, Vanderwinden JM, Letesson JJ, Muraille E.

Front Immunol. 2018 Aug 10;9:1856. doi: 10.3389/fimmu.2018.01856. eCollection 2018.


Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.

Roupie V, Pidot SJ, Einarsdottir T, Van Den Poel C, Jurion F, Stinear TP, Huygen K.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2604. doi: 10.1371/journal.pntd.0002604. eCollection 2014.


Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen.

Bruffaerts N, Romano M, Denis O, Jurion F, Huygen K.

Vaccines (Basel). 2014 Mar 5;2(1):181-95. doi: 10.3390/vaccines2010181.


Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.

Todoroff J, Lemaire MM, Fillee C, Jurion F, Renauld JC, Huygen K, Vanbever R.

PLoS One. 2013 May 10;8(5):e63344. doi: 10.1371/journal.pone.0063344. Print 2013.


Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis.

Waeckerle-Men Y, Bruffaerts N, Liang Y, Jurion F, Sander P, Kündig TM, Huygen K, Johansen P.

Vaccine. 2013 Feb 4;31(7):1057-64. doi: 10.1016/j.vaccine.2012.12.034. Epub 2012 Dec 25.


Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c).

Romano M, Rindi L, Korf H, Bonanni D, Adnet PY, Jurion F, Garzelli C, Huygen K.

Vaccine. 2008 Nov 11;26(48):6053-63. doi: 10.1016/j.vaccine.2008.09.025. Epub 2008 Sep 24.


Evidence for frequent divergence impairment in French dyslexic children: deficit of convergence relaxation or of divergence per se?

Kapoula Z, Bucci MP, Jurion F, Ayoun J, Afkhami F, Brémond-Gignac D.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):931-6. Epub 2006 Dec 21.


Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

Romano M, Roupie V, Wang XM, Denis O, Jurion F, Adnet PY, Laali R, Huygen K.

Immunology. 2006 Jul;118(3):321-32.


Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.

D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N, Vanonckelen A, Palfliet K, Huygen K.

Infect Immun. 2003 Jan;71(1):483-93.


Improved tuberculosis DNA vaccines by formulation in cationic lipids.

D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F, Palfliet K, Castiglioni N, Vanonckelen A, Wheeler C, Huygen K.

Infect Immun. 2002 Jul;70(7):3681-8.


What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?

Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffé M, Lefèvre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J, Huygen K.

Int J Cancer. 2000 Sep 15;87(6):844-52.


What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC.

Eur Urol. 2000 Apr;37(4):470-7.


Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.

Zlotta AR, Drowart A, Van Vooren JP, Shekarsarai H, De Cock M, Pirson M, Palfliet K, Jurion F, Simon J, Schulman CC, Huygen K.

J Urol. 1998 Jun;159(6):1885-91.


Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection.

Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, Ooms J, Saman E, Ulmer JB, Content J, Huygen K.

Infect Immun. 1998 Apr;66(4):1527-33.


Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group.

Lozes E, Denis O, Drowart A, Jurion F, Palfliet K, Vanonckelen A, De Bruyn J, De Cock M, Van Vooren JP, Huygen K.

Scand J Immunol. 1997 Jul;46(1):16-26.


Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.

Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Mascart F, Simon J, Schulman CC, Van Vooren JP.

Clin Exp Immunol. 1997 Jul;109(1):157-65.


[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].

Shekarsarai H, Zlotta AR, Drowart A, Van Vooren JP, De Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.

Acta Urol Belg. 1997 Mar;65(1):1-4. French.


Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.

Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.

J Urol. 1997 Feb;157(2):492-8.


Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG.

Huygen K, Lozes E, Gilles B, Drowart A, Palfliet K, Jurion F, Roland I, Art M, Dufaux M, Nyabenda J, et al.

Infect Immun. 1994 Feb;62(2):363-70.


Antibody repertoire against culture filtrate antigens in wild house mice infected with Mycobacterium bovis BCG.

Huygen K, Palfliet K, Jurion F, Lenoir C, van Vooren JP.

Clin Exp Immunol. 1990 Nov;82(2):369-72.


H-2-linked control of in vitro gamma interferon production in response to a 32-kilodalton antigen (P32) of Mycobacterium bovis bacillus Calmette-Guérin.

Huygen K, Palfliet K, Jurion F, Hilgers J, ten Berg R, Van Vooren JP, De Bruyn J.

Infect Immun. 1988 Dec;56(12):3196-200.


Supplemental Content

Loading ...
Support Center